Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human IL-1 RII Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: R&D Systems MAB263SP
This item is not returnable.
View return policy
Description
IL-1 RII Monoclonal specifically detects IL-1 RII in Human samples. It is validated for Western Blot, Neutralization, Immunocytochemistry.Specifications
IL-1 RII | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
beta, CD121b, CD121b antigen, IL-1 R beta, IL1R2, IL1RBCD121 antigen-like family member B, IL-1R-beta, IL1RII, IL-1RII, IL-1RT2, IL-1RT-2, interleukin 1 receptor, type II, Interleukin-1 receptor beta, MGC47725 | |
Mouse | |
Protein A or G purified from ascites | |
RUO | |
7850 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2a |
Western Blot, Neutralization, Immunocytochemistry | |
32437 | |
Western Blot 1 ug/mL, Neutralization 2-6 ug/mL, Immunocytochemistry 8-25 ug/mL | |
P27930 | |
IL1R2 | |
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IL-1 RII Phe14-Glu343 (Glu297Gly) Accession # P27930 | |
25 μg | |
Primary | |
Detects human IL-1 RII in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) IL-1 RI, rhIL-18 R, and recombinant mouse IL-18 R is observed. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction